Please login to the form below

Not currently logged in
Email:
Password:

AZ stops Galida development

Another blow to Anglo-Swedish firm's pipeline as diabetes drug project is shelved

AstraZeneca's (AZ) pipeline hopes suffered another dent after the company said it had cancelled development of its late-stage diabetes drug, Galida.

The news will come as a blow to the Anglo-Swedish firm, which had been hoping to strengthen a pipeline that has been hit by high-profile failures in the past couple of years. Galida had reached phase III clinical trials and was regarded as a promising new treatment for type 2 diabetes.

For its part, AZ had warned investors that the Galida project came with several risks. The firm said that, after analysing results from the first four of eight phase III clinical trials and one phase II trial, it had concluded that the drug was ìunlikely to offer patients significant advantage over currently available therapyî.

AZ added that there was no immediate safety concern for the 2,245 patients taking Galida within clinical trials. The trials will now be brought to a close and doctors will be advised to switch patients to alternative therapies.

ìWe have acknowledged that Galida was in a class with a high degree of uncertainty and the decision to discontinue is disappointing,î said AZ chief executive, David Brennan, in a statement.

Analysts said they were not overly surprised by the news, as there had already been concerns about the drug's overall risk-benefit profile.

ìGalida was put under a cloud well over a year ago when AZ placed its development under review,î said Williams de Broe analyst, Peter Cartwright. ìHowever, pulling another phase III product is not good and emphasises the need for AstraZeneca to fill its pipeline.î

AZ has recently appointed John Goddard, previously chief financial officer, to oversee the company's licensing strategy, in a bid to buy in more drugs to bolster the pipeline.

ìIt's apparent to me and a number of people on the management team that there are more external opportunities that we should be taking advantage of,î said Brennan.

Cartwright described Goddard's appointment as a ìreaction to eventsî.

ìAZ's cupboard is looking bare and they needed to do something about it,î he commented.

In February, AZ withdrew its controversial anticoagulant, Exanta, from the market and terminated its development due to links with liver injury.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics